In recent years FDA has undertaken several means to facilitate the consideration of new drug applications by creating various mechanisms for expedited review for either new drugs or new indications for existing drugs. Prior to 2012, there had long been … Continue reading ?
Autumn is almost here! Curl up with your favorite extra hot skim grande Pumpkin Spice blog and savor our latest seasonal harvest of Drug Channels news: Walgreens Specialty Pharmacy tells us a teeny bit about its business Dispensing oncology...Show More Summary
PLOS Medicine’s Associate Editor Tom McBride interviews Bruce Miller, Guest Editor for our Special Issue on Dementia, in the first of two podcasts. Dr. Bruce Miller is the Director of the Memory and Aging Center at
Time for our annual review of the latest Inc. 5000 list, the magazine’s annual ranking of the fastest-growing private companies in the United States. The list offers a valuable snapshot of the dynamic specialty pharmacy industry. We have identified 12 specialty pharmacies on the 2016 list, which is based upon revenue growth from 2012 to 2015. Show More Summary
CBI’s 8th Federal Pricing and Reporting – VA DoD PHSNovember 16-17, 2016 | Philadelphia, PAAt the 8th Federal Pricing and Reporting Summit, gain strategies to achieve contracting excellence and compliance with the “Big Four” federal programs. Show More Summary
Kids are back in school. The air is kinder, gentler and less harsh than the last heated days of summer, though summer tries to hang on some days, it is ebbing into Autumn. Halloween candy has already appeared in stores. … Continue reading ?
I was quoted in an AdAge story (see embedded summary at the end of this post) about the recent spate of scary drug ads seen on TV and in print. The title of the article - "Halloween Already? Big Pharma Marketers Try Terror Tactics to...Show More Summary
For better or worse, Mylan’s EpiPen controversy has started an intriguing dialogue about my favorite subject: the economics of U.S. drug channels. Many news stories have tried to explain how a prescription drug’s list price differs from the ultimate net price paid by insurers and the government. Show More Summary
Pharmaceutical Strategies for Value-Based Contracting SummitManaging Customer Expectations When Designing Outcome-Based ContractsOctober 24 - 25, 2016 • Alexandria, VA • Westin AlexandriaCustomers continue to evolve traditional contracting structures and strategies as the health care market dynamics shift towards value-based care. Show More Summary
As PLOS Pathogens announces a call for papers on co- and polymicrobial infections and diseases, the Editorial team highlights the importance of this work to our community. We aim to focus specifically on work that
ICYMI: Last week, Walgreens Boots Alliance (WBA) and Prime Therapeutics rolled out a highly innovative partnership. It could have wide-ranging implications for the drug channel’s next phase. This novel union aligns a pharmacy benefit...Show More Summary
PLOS Neglected Tropical Diseases co-Editors-in-Chief Peter J Hotez and Serap Aksoy discuss new research reporting that Culex mosquitos apparently cannot transmit Zika. As Zika infects large numbers of immunologically naïve populations in the Americas, significant concern
CBI’s Outcomes-Based Contracting SummitOctober 17-18, 2016 | Philadelphia, PAwww.cbinet.com/outcomescontractingAre you prepared to navigate the intricacies of value-based contracting? Mark your calendar for CBI’s Outcomes-Based Contracting...Show More Summary
In what's been described as a "surprise move" (here) the FDA recently published a notice that it will hold a 2-day public hearing this November to obtain "input on issues" related to off-label product communications about by pharmaceutical and medical device companies. Show More Summary